The lancet oncology
-
The lancet oncology · Jul 2022
Observational StudyNew strategies for standardised and appropriate access to a complete acute lymphocytic leukaemia diagnostic panel for children in Mexico: an observational study.
Approximately 50% of all childhood cancer cases in Mexico are acute lymphocytic leukaemia. Survival rates are suboptimal when compared with those in high-income countries, and poor access to standardised testing and treatment has been identified as a contributing factor. Mexico in Alliance with St Jude (MAS) is a multisite intersectoral collaboration created in 2016 to improve childhood cancer outcomes. MAS conducted a retrospective analysis of childhood acute lymphocytic leukaemia where diagnostic disparities and risk-group classification emerged as a challenge; 419 (72%) of 578 of patients with confirmed acute lymphocytic leukaemia did not have access supporting fluorescent in-situ hybridisation (FISH) testing and 226 (39%) of 578 patients did not have minimal residual disease evaluation. FISH results were reported in a median of 15 days (SD 17) and cytogenetic results were reported after a median of 22 days (SD 27). In response, MAS launched The Bridge Project, in 2019, to improve access, accuracy, and timeliness of diagnostic information for children with acute lymphocytic leukaemia in Mexico. ⋯ Fundación Gonzalo Río Arronte (Mexico City, Mexico); Casa de la Amistad para niños con Cáncer (Mexico City, Mexico); St Jude Children's Research Hospital (Memphis, TN, USA).
-
The lancet oncology · Jul 2022
Induction-maintenance approach for the chronic phase of chronic myeloid leukaemia (IMPACT-I): a prospective, single-arm, phase 2 study.
Imatinib and second-generation tyrosine-kinase inhibitors (2G-TKIs) are standard options for the first-line treatment of chronic myeloid leukaemia. Although 2G-TKIs are superior to imatinib in terms of rate and depth of molecular response, they do not bring significant improvements in survival outcomes, and concerns exist over their long-term safety. The availability of a generic formulation makes imatinib an attractive economical option. We propose a novel induction-maintenance approach that would have the advantage of inducing early molecular response with 2G-TKIs, followed by maintenance with the safer and more affordable imatinib. ⋯ 2017 Young Investigator Research Grant from the Hong Kong College of Physicians.
-
The lancet oncology · Jul 2022
Impact of health insurance type on access to vaccination and mortality due to COVID-19 on patients with cancer in Colombia: a cohort study.
In Colombia, all paid workers earning minimum wage or higher contribute part of their salary for access to the national health-care system through a type of insurance called contributive plan, which supports the remaining low-income population that is enrolled on the subsidised plan. During the COVID-19 pandemic, Colombia documented high mortality rate in patients with cancer, with higher mortality among low-income patients, according to data from our national registry of COVID-19 infection in patients with cancer. The aim of this research was to establish the differential access to COVID-19 vaccination depending on health insurance type, and its impact on mortality due to COVID-19 infection. ⋯ None.
-
The lancet oncology · Jul 2022
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study.
Aggressive medical care can increase suffering and the health-care burden on patients with advanced haematological malignancies. Our palliative care team has been pioneering an integrated palliative care (IPC) programme for patients with advanced haematological malignancies in Hong Kong since 2018. The aim of the study was to evaluate the effect of IPC on the administration of chemotherapy or other treatments within the 14 days before death; multiple (more than one) emergency department visits within the 90 days before death; multiple (more than one) unplanned hospitalisations within the 90 days before death; and intensive care unit admission within the 90 days before death. ⋯ None.
-
The lancet oncology · Jul 2022
CK2α as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling.
Breast cancer is the most common cancer in Japanese and Asian women. Although the 5-year survival rate of these patients is relatively high, recurrences and fatalities do occur. The objective of this work was to develop a reliable prognostic indicator to guide therapeutic intervention without waiting for recurrence or metastasis. ⋯ Japan Agency for Medical Research and Development (grant number 20lm0203006j0004).